Kaplan-Meier survival plots for patients with MM.

The curves are separated by IGF-1 levels: “low” IGF-1 (25th percentile, < 13 nM) compared to remaining patients (IGF-1 ≥ 13 nM). Follow-up periods did not differ between the groups. (A) The 127 patients entered in the study. Median survival was not reached in the patient group with low IGF-1 (n = 32), compared to a median survival of 62 months in the remaining 95 patients (P = .006). (B) This difference was also evident in the 94 patients treated with the intended protocol. Median survival was not reached in the patient group with low IGF-1 (n = 27) compared to a median survival of 70 months in the remaining 67 patients; P = .03).